Although this model performs better than the current 20/2/20 model and uses the new cytogenetic classification, further refinement of the model could be achieved by leveraging next-generation sequencing from blood and BM samples as well as the addition of circulating tumor cells, and the use of highly sensitive technologies for detecting M-protein levels, such as mass spectrometry, which can also be included in future studies16,29-30. This evidence concerns the gene MYOM2 and neoplasm.